Total astragalus saponins attenuate primary sclerosing cholangitis in mice by upregulation of TGR5

Abstract

AbstractTotal astragalus saponins (TAS) are the main active components of astragali radix, and have potent anti‐hepatic fibrosis effect. However, the therapeutic efficacy of TAS and their potential mechanisms in the treatment of primary sclerosing cholangitis (PSC) remain unclear. In this study, two mouse models of PSC, including 3,5‐Diethoxycarbonyl‐1,4‐Dihydro‐2,4,6‐Collidine (DDC)‐induced PSC and Mdr2−/− spontaneous PSC, and the Tgr5−/− mice were used to investigate the therapeutic effect and mechanisms of TAS. Treatment with TAS, particularly with a dose of 56 mg/kg, significantly ameliorated the PSC‐related liver injury, cholestasis, collagen deposition, ductular reaction (DR), and fibrosis in the DDC‐induced and Mdr2−/−spontaneous PSC mice. Furthermore, treatment with TAS significantly mitigated the PSC‐related inflammatory responses in vivo and HIBEpiC cells by inhibiting the expression of TNF‐α, IL‐6, and IL‐1β. Mechanistically, treatment with TAS rescued the PSC‐decreased hepatic TGR5 expression to attenuate the NF‐κB p65 phosphorylation. Notably, the therapeutic efficacy of TAS on PSC in DDC‐induced mice was abrogated in Tgr5−/− mice, suggesting the anti‐PSC effect of TAS may depend on enhancing TGR5 expression. In conclusion, TAS ameliorated DR, inflammation and liver fibrosis in both models of PSC mice by rescuing TGR5 expression. Our findings may aid in the design of new therapeutic strategies for the treatment of PSC.